Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 14 | 2023 | 1373 | 3.240 |
Why?
|
| Glucokinase | 6 | 2023 | 61 | 2.220 |
Why?
|
| Genetic Testing | 8 | 2023 | 535 | 2.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2021 | 567 | 1.600 |
Why?
|
| Insulin Infusion Systems | 2 | 2021 | 36 | 1.530 |
Why?
|
| Pancreas, Artificial | 2 | 2021 | 28 | 1.490 |
Why?
|
| Pregnancy in Diabetics | 2 | 2018 | 37 | 1.300 |
Why?
|
| Insulin | 6 | 2021 | 1160 | 1.230 |
Why?
|
| Hypoglycemic Agents | 6 | 2020 | 378 | 0.980 |
Why?
|
| Diabetes Mellitus | 8 | 2023 | 806 | 0.920 |
Why?
|
| Self-Management | 1 | 2021 | 29 | 0.790 |
Why?
|
| Mutation | 11 | 2023 | 3968 | 0.760 |
Why?
|
| Patient Participation | 1 | 2020 | 216 | 0.640 |
Why?
|
| Registries | 6 | 2023 | 702 | 0.610 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 247 | 0.590 |
Why?
|
| Sulfonylurea Compounds | 6 | 2017 | 64 | 0.570 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 454 | 0.570 |
Why?
|
| Blood Glucose | 1 | 2020 | 873 | 0.560 |
Why?
|
| Mass Screening | 1 | 2019 | 618 | 0.510 |
Why?
|
| Adolescent | 12 | 2020 | 8981 | 0.500 |
Why?
|
| Adolescent Behavior | 1 | 2015 | 106 | 0.490 |
Why?
|
| Child | 10 | 2020 | 6927 | 0.470 |
Why?
|
| Medication Adherence | 1 | 2015 | 129 | 0.470 |
Why?
|
| Precision Medicine | 4 | 2023 | 395 | 0.460 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 5 | 2017 | 119 | 0.460 |
Why?
|
| Models, Theoretical | 2 | 2019 | 482 | 0.410 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2021 | 57 | 0.380 |
Why?
|
| Infant, Newborn | 8 | 2019 | 2379 | 0.340 |
Why?
|
| Humans | 26 | 2023 | 86643 | 0.330 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2019 | 138 | 0.320 |
Why?
|
| Genomics | 1 | 2013 | 720 | 0.310 |
Why?
|
| Hyperglycemia | 2 | 2019 | 176 | 0.310 |
Why?
|
| Female | 17 | 2023 | 44532 | 0.280 |
Why?
|
| Young Adult | 6 | 2020 | 5976 | 0.270 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 3 | 2023 | 80 | 0.270 |
Why?
|
| Child, Preschool | 6 | 2019 | 3612 | 0.270 |
Why?
|
| Male | 16 | 2023 | 40965 | 0.260 |
Why?
|
| United States | 5 | 2021 | 6672 | 0.230 |
Why?
|
| Biomarkers | 2 | 2020 | 1718 | 0.230 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2023 | 5 | 0.230 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 2 | 2013 | 30 | 0.220 |
Why?
|
| Adult | 9 | 2020 | 25648 | 0.210 |
Why?
|
| Life Expectancy | 2 | 2019 | 86 | 0.210 |
Why?
|
| Pregnancy | 2 | 2018 | 2894 | 0.200 |
Why?
|
| Computer Literacy | 1 | 2020 | 2 | 0.190 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 127 | 0.190 |
Why?
|
| Attitude to Computers | 1 | 2020 | 12 | 0.190 |
Why?
|
| Infant | 5 | 2019 | 3046 | 0.190 |
Why?
|
| Monitoring, Ambulatory | 1 | 2020 | 32 | 0.190 |
Why?
|
| Diffusion of Innovation | 1 | 2020 | 71 | 0.180 |
Why?
|
| Health Care Surveys | 1 | 2020 | 278 | 0.180 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 51 | 0.170 |
Why?
|
| Sleep | 1 | 2023 | 444 | 0.170 |
Why?
|
| Birth Weight | 1 | 2018 | 145 | 0.160 |
Why?
|
| Hepatocyte Nuclear Factors | 1 | 2018 | 2 | 0.160 |
Why?
|
| Siblings | 2 | 2016 | 111 | 0.160 |
Why?
|
| Genetic Markers | 1 | 2019 | 476 | 0.160 |
Why?
|
| Abortion, Spontaneous | 1 | 2018 | 66 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 160 | 0.160 |
Why?
|
| Treatment Outcome | 3 | 2020 | 7993 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2019 | 238 | 0.150 |
Why?
|
| Pedigree | 1 | 2019 | 966 | 0.150 |
Why?
|
| Hypoglycemia | 1 | 2017 | 107 | 0.150 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 455 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2019 | 377 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 508 | 0.140 |
Why?
|
| Potassium Channels | 1 | 2018 | 340 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1673 | 0.130 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2015 | 13 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 456 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 29 | 0.130 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2016 | 111 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 636 | 0.130 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 195 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 1565 | 0.120 |
Why?
|
| Prevalence | 1 | 2018 | 1239 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1621 | 0.110 |
Why?
|
| Middle Aged | 6 | 2023 | 25028 | 0.100 |
Why?
|
| Internet | 1 | 2011 | 312 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2011 | 429 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 536 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2013 | 2767 | 0.070 |
Why?
|
| Sulfonylurea Receptors | 2 | 2014 | 50 | 0.060 |
Why?
|
| Consensus | 1 | 2023 | 335 | 0.050 |
Why?
|
| Family | 1 | 2023 | 311 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 429 | 0.050 |
Why?
|
| Cost Savings | 1 | 2017 | 66 | 0.040 |
Why?
|
| Markov Chains | 1 | 2017 | 125 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 185 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 114 | 0.040 |
Why?
|
| Neurologic Manifestations | 1 | 2016 | 11 | 0.040 |
Why?
|
| Selection Bias | 1 | 2016 | 37 | 0.040 |
Why?
|
| Glyburide | 1 | 2015 | 32 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 339 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2016 | 276 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 310 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 502 | 0.030 |
Why?
|
| Risk Factors | 1 | 2023 | 5417 | 0.030 |
Why?
|
| Receptors, Drug | 1 | 2011 | 54 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1805 | 0.030 |
Why?
|
| Epidemiologic Research Design | 1 | 2011 | 22 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2015 | 8489 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 141 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1961 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2011 | 101 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1851 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 2378 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2010 | 342 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1019 | 0.020 |
Why?
|
| Aged | 2 | 2017 | 18415 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1577 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 1379 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 1830 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 26582 | 0.010 |
Why?
|